這是一項單中心、前瞻性隊列研究。連續患有代償性肝病並接受根治性治療的肝細胞癌（HCC）患者將獲邀參與本研究。研究隨訪期為五年。主要終點為新發高風險靜脈曲張、肝功能失代償及肝臟相關死亡的複合結局。
適應症：HCC - Hepatocellular Carcinoma、Cirrhosis
收案條件
納入條件
- Aged 18 or above
- Known chronic liver disease(s)
- HCC for curative-intent treatment (defined by HCC diagnosed with typical radiological features or histology, and planned for surgical resection or local ablative therapy as a curative-intent treatment)
排除條件
- Current or history of decompensated liver cirrhosis (i.e. Child's C cirrhosis, prior decompensating events such as ascites, variceal bleeding, hepatic encephalopathy and hepatorenal syndrome)
- o Child's B cirrhosis without decompensating events is not excluded
- Past history of HCC (ie. The current HCC is a recurrence of priorly treated HCC or a second de novo HCC after previous first HCC)
- Non-primary liver tumour (such as secondary liver tumour due to metastasis from another distant primary tumour)
- History of liver transplantation or plan for liver transplantation as the modality of curative-intent HCC treatment
- Asplenism or history of splenectomy
- Contraindication to OGD (eg. Intestinal perforation of obstruction)
- Serious medical illness with limited life expectancy of less than 6 months
- Pregnancy
- Unable to obtain or refusal of informed consent from patient
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。